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Abstract
Background. Microbial infections are the most serious
complications associated with indwelling central venous
catheters. A catheter lock solution that is both antibacterial
and antithrombotic is needed. The goal of this study was
to determine whether a new catheter lock solution contain-
ing citrate, methylene blue and parabens has antimicrobial
properties against planktonic bacteria and against sessile
bacteria within a biofilm. These effects were compared to
the antimicrobial properties of heparin at 2500 units/ml.
Methods. The tested solution (C/MB/P comprising 7%
sodium citrate, 0.05% methylene blue and 0.165%
parabens) and individual components were challenged
against gram-positive and gram-negative organisms and
fungi. Control solutions were heparin with preservatives.
Studies included evaluation of eradication of planktonic
bacteria and sessile organisms in a biofilm grown on poly-
meric and glass coupons. Biofilm samples were inspected
by scanning electron microscopy, atomic force microscopy
and vital stains.
Results. The C/MB/P solution, contrary to heparin, kills
most tested planktonic microorganisms within 1 h of in-
cubation. All tested organisms have an MIC of 25% or
less of the original concentration of a new catheter lock.
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Bacteria strains did not develop resistance over more than
40 passages of culture suspensions. The C/MB/P solution
isabletokillnearlyallsessilebacteriainbiofilmgrowthon
plastic or glass discs in 1 h. Microscopic methods demon-
strated extensive physical elimination of biofilm deposits
from treated coupons. In contrast, heparin had a minimal
effect on planktonic or biofilm organisms.
Conclusions. The new multicomponent lock solution
has strong antimicrobial properties against both plank-
tonic and sessile microorganisms. By comparison, heparin
with preservative has weak antibacterial properties against
planktonic and biofilm bacteria. The tested catheter lock
may have usefulness in preventing bacterial colonization of
haemodialysis catheters and diminishing the incidence of
catheter-related bacteraemia.
Keywords: biofilm; catheter infection; CRBSI; haemodialysis; lock
solution
Introduction
Catheter-related blood stream infection (CRBSI), espe-
cially in haemodialysis (HD) patients, is a problem of
epidemic proportion and serious morbidity and mortality
[1,2]. Every year, more than 320000 patients in the United
StatesundergoHDtreatmentand>25%(80000)usedialy-
sis catheters for access [3]. The incidence of CRBSI ranges
from 1.6 to 6.1 episodes per 1000 catheter-days [4–7]. As-
suming three CRBSI events per 1000 catheter-days for HD
patients, there are about 100000 CRBSI episodes per year
among HD patients. With a mortality rate of 5–10% for
each CRBSI event [5], there are 5000–10000 HD patient
deaths per year as a result of CRBSI. About one-third of
CRBSI episodes require in-patient hospitalization. A num-
ber of strategies have been tried to reduce the incidence of
CRBSI,includingtheuseofstricthygienicmeasures,maxi-
mal barrier precaution, catheter dressing, catheter coatings,
nasal decolonization and prophylactic antibiotic ointment
at the exit site [8,9]. In order to prevent intraluminal colo-
nization and the development of a biofilm, installation of
an antimicrobial catheter lock solution (CLS) has been re-
cently proposed [10]. Eight randomized clinical trials have
compared the frequency of catheter-related bacteraemia in
patients receiving a prophylactic antimicrobial CLS versus
patients receiving standard heparin locks. Six studies used
an antibiotic lock (gentamicin, cefazolin with gentamicin,
minocycline, minocycline/EDTA or cefotaxime) [6,7,11–
14], one study used taurolidine, [15] and one used 30%
citrate [5]. These trials have shown more than 3-fold reduc-
tion in the occurrence of CRBSI, together with decreases
in morbidity and mortality versus use of heparin as CLS
[16–18].
Despite promising results with antibacterial CLS, there
areanumberofpotentialproblemswithprophylacticuseof
antibiotics.Therearegrowingnumbersofpatientswithmi-
crobial isolates resistant to antibiotics such as methicillin,
gentamicin and vancomycin [19,20]. The spillage of up to
15% of the catheter volume into the patient’s blood [21]
can result in the development of antibiotic-resistant strains
of Staphylococcus or Pseudomonas [22], systemic toxi-
city and aminoglycoside ototoxicity. Other disadvantages
include the incompatibility of antibiotics such as gentam-
icin and cephalosporins with heparin [6,7]. Heparin as a
CLS causes a bleeding risk due to systemic anticoagulation
and, in some patients, heparin-induced thrombocytopenia
[5,23,24].
CRBSI results both from intraluminal contamination
with transfer of planktonic bacteria to the blood and re-
lease of bacteria within biofilms. Microorganisms embed-
dedinabiofilmencounterauniquemicroenvironmentwith
higher cell density, growth rates and gene transcription ver-
susplanktonic bacteria. Sessilebacteriainbiofilmshave an
inherent resistance to antibiotics. As many as 60% of bac-
terial infections treated by physicians are related to biofilm
formation and are not easily eradicated by conventional
antibiotic therapy [25].
There is a great need for an antibacterial CLS based
on antiseptics rather than antibiotics [26–28]. Antiseptics
kill bacteria through physical effects rather than specific
biochemical pathways and may not induce microbial re-
sistance. In this publication, we describe in vitro tests of
antibacterial properties of the new CLS against planktonic
andsessilebacteria,andmicroscopicstudiesofphysicalef-
fects of the lock solution on a biofilm. We compared these
results to antibacterial properties of heparin with parabens
as a preservative.
Methods
Composition of the citrate/MB/parabens lock solution (C/MB/P), and
heparin solution
A new CLS (C/MB/P) comprises 7% (w/v) sodium citrate buffer (0.24 M
of pH 6.2), 0.05% methylene blue (MB), 0.15% methyl paraben (MP) and
0.015% propyl paraben (PP). A solution of heparin 5000 units/ml with
1.5 mg/ml MP and 0.15 mg/ml of PP (Abraxis Pharmaceutical Products,
Schaumburg,IL)wasdiluted1:1withsterilewaterjustbeforeexperiments,
yielding a concentration of 2500 units/ml (a medium dose concentration).
Planktonic bacteria tests
Antibacterial properties of C/MB/P, individual components of a new lock
solution and heparin were tested against gram-positive and gram-negative
strains of bacteria and fungi obtained from ATCC and from hospital iso-
lates. Single colonies from fresh Trypticase Soy Agar (TSA) plates with
sheep blood were used for preparation of overnight inocula. Twenty millil-
itre C/MB/P solutions containing 5% bovine serum albumin (BSA) were
mixed with 1 ml of Luria-Bertani (LB) broth to augment bacterial growth
as might occur with blood entry to the dialysis catheter tip. Finally, 10 µl
of each microbial inoculum(≥106 CFU/ml for bacteria or≥104 forfungi)
was added separately to each solution, mixed and 10 µl withdrawn im-
mediately for preparation of serial 10× dilutions that were spread onto
TSA plates in order to enumerate colony forming units per ml (CFU/ml)
in time 0. Undiluted solutions were also plated and the remaining volumes
filtrated through a 0.45 µm filter that, after washing with sterile saline,
was placed on TSA and incubated overnight. The limit of detection was
≤101 CFU/ml. A saline control prepared as above was also included for
each experiment.
Erlenmeyerflaskswithtestsolutionswereplacedonashakerincubator
(for bacteria 200 RPM, 37◦C; for fungi 50 RPM and 25◦C), and samples
were taken at time intervals of 0.5, 1.0, 2.0 h and after 1, 2, 3 days
for plating as described above. For comparison, a heparin solution was
tested in a similar manner. Each experiment was repeated three times. We
also ran identical experiments with each individual compound that was
part of a new lock solution. They included citrate only, citrate/MB and
citrate/mixture of parabens.Antimicrobial catheter lock solution 1939
Minimum inhibitory concentration (MIC) study
TheMICofaC/MB/Psolutionagainstapanelofgram-positiveandgram-
negative pathogens was determined by microtitre plate dilution assay as
described by the National Committee for Clinical Laboratory Standards
[29].Overnightinoculaweredilutedtomatchthe0.5McFarlandstandards
(1 to 2 × 108) and then further diluted 1:10 with Mueller Hinton (MH)
broth. The microtitre tray contained 100 µl of 2-fold serial dilutions of
the full-strength test solution distributed in six rows (i.e. concentrations of
50% down to 1.56% of the initial concentration) and 5 µl broth suspen-
sions of the test microorganisms in the wells. Positive controls contained
saline instead of a test solution; negative controls contained sterile broth
instead of microbial suspension. MIC end points were determined by vi-
sual inspection after overnight incubation at 37◦C for 24 h (bacteria) and
28◦C for 24/48 h (yeast). Where colour intensity interfered with interpre-
tation, cultures on MH agar were employed as confirmatory tests. Final
results were expressed as the mean of three repetitions and presented as
the percent of the original test solution concentration. The MIC was the
lowest concentration of the test solution that completely inhibited growth
of the microorganism in the well.
Bacterial resistance study
Resistance development studies were designed on the basis of MIC re-
sults. Gram-negative (Escherichia coli ATCC 25922) and gram-positive
(Staphylococcus aureus ATCC 29213—MRSA) organisms were tested in
capped sterile tubes. A single colony of each tested bacteria from fresh
TSA plates containing sheep blood was used to prepare overnight inocu-
lum in LB broth. The suspension of cells was next diluted with broth to
a concentration of ∼1–2 × 106 CFU/ml. Concentrations of the test solu-
tion close to the previously established MIC were prepared in LB broth
with 0.2% glucose as an additional carbon source. One milliliter of each
concentration was dispensed into sterile capped tubes, and 10 µlo ft h e
adjusted cell suspension was added to all tubes. After 24 h of incubation,
10 µl of cell suspension was passed to a new tube with the same dilution
of the test solution to check continued survival in that concentration. Also,
an additional 10 µl of bacteria from the strongest concentration showing
survivalwaspassed toatubecontaininganevenhigherconcentration;this
was to determine if continued exposure to the lock solution made them
abletoadaptandsurvive.Thecontrolwaspassedtoanewfreshbrothwith
glucose. In concentrations too dark to assess visually (due to the concen-
tration of MB), subcultures were employed each day to confirm viability
of cells in tested solutions. The experiment was carried out in duplicate
for 40 days to assess any change over time that might indicate increasing
resistance that would allow continued survival in a higher concentration
of the test solution than at Day 1.
Biofilm studies with various organisms
The biofilm in preliminary studies was developed in Erlenmeyer flasks
on circular carbothane or glass coupons (d = 1.27 cm). Sterile coupons
were incubated with microbes in 10 ml LB broth containing 0.2% glucose
at 37◦C and 160 RPM (25◦C and 50 RPM for Candida albicans). The
biofilm formation was tested for a few hours and up to 7 days. If incuba-
tion was longer than 1 day, coupons were transferred into fresh medium at
24-hintervals.Onthebasisofattainedresults,allfurtherexperimentswere
performed on biofilms developed within 24 h of incubation. At the end of
incubation, coupons were gently rinsed in sterile saline to remove plank-
tonic bacteria. Coupons were divided into two groups: control that served
as a baseline for biofilm growth and tested discs that were additionally
exposed to a new CLS for 1 h. The biofilm was removed from coupons by
short 15 s vortexing followed by a 2 min sonicating procedure and again
vortexing. Next, serial dilutions were applied to TSA plates for bacterial
enumeration. Other coupons with a biofilm before and after 1-h treatment
with C/MB/P were examined by various optical methods: scanning elec-
tronmicroscopy(SEM),atomicforcemicroscopy(AFM)andfluorescence
microscopy (FM) follow standard method protocols i.e. fixation with glu-
taraldehydeandcriticaldryingforSEM,andstainingwithLIVE/DEAD
R  
BacLightTM bacterial viability dye for FM. The LIVE/DEAD stain makes
useoftwodifferentstains:Cyto9andpropidiumiodide.Cyto9istakenup
by cells having charged membranes due to the presence of proton motive
force (results in cells stained green). Propidium iodide is a DNA stain that
only enters cells having a compromised/breached membrane (results in
cells stained in red).
Fig.1. ComparisonofantimicrobialeffectivenessofheparinandC/MB/P
after incubation with microorganisms’ broth suspension for 60 min, 24,
4 8a n d7 2h .
Biofilm studies staphylococcus in flow cell
The effectiveness of C/MB/P and heparin against a clinical isolate of S.
aureus was also investigated in a flow cell bioreactor for a period of 16
days. In long-lasting experiments, hydraulic shear is a crucial factor in
the development of a biofilm and a stable shear rate is best achieved in a
bioreactor.Thetechniquesweredesignedtoreplicateexposureofcatheters
to blood-side contamination during dialysis and locks with CLS between
treatments. Sterile 1 × 2 cm carbothane strips presoaked with human
serum were aseptically loaded into flow cells. The strips were challenged
for 3 h with ∼103 CFU/ml bacterial suspensions before the appropriate
lock solutions were introduced. The locks were left in place for 24-, 48- or
72-h periods simulating a catheter lock during three times weekly HD, and
3 h bacterial challenges in-between simulating dialysis with contaminated
blood.So-calleddirtysamplesweresubjectedto48hofbacterialchallenge
with S. aureus before they were inserted to the bioreactor cells for testing.
After a predetermined number of cycles of plasma and lock solution,
each strip was manually scraped on the outer surface in a consistent and
repeatable manner and then sonicated (1 min) and vortexed (30 s) in a
neutralizing solution. The resultant bacterial solutions were diluted with
sterile saline and plated in triplicate on TSA for colony enumeration.
Statistical analysis
For planktonic bacteria, the log colony count at 24 h was compared for
variouscombinationsofthecomponentsofthelocksolution.Thestandard
deviation was determined by standard formulas. P-values were calculated
using Student’s t-test (two-tailed, paired) with Excel software.
Results
The results of the comparison study of antimicrobial effec-
tiveness between heparin used commonly to lock the lumen
of catheters after HD sessions and our solution are shown
in Figure 1. Heparin is mostly ineffective in the inhibition
of growth of tested microorganisms. A modest reduction in
the range of 3–4 logs of living cells was achieved only with
StaphyloccusepidermidisandPseudomonasaeruginosaaf-
ter prolonged 48–72 h of incubation. In contrast, C/MB/P
revealedpotentantimicrobialpropertiesagainstallchecked
microorganisms. Most noticeably, 1-h contact of microbes
with this solution is sufficient to eliminate the majority of
planktonic cells in test solutions. Fungi like C. albicans or
Aspergillus niger survived a little bit longer, but there was
no subcultured fungal activity after 24-h’ exposure of cells
to the solution.
The C/MB/P solution is composed of several com-
pounds. Each of them, if used separately in the concen-
tration employed in the final product, discloses a weak
antimicrobial effect. This effect depends upon the strain of1940 J. Steczko et al.
Fig. 2. Antimicrobial effectiveness C/MB/P and its components in the presence of media and albumin versus Staphylococcus aureus (A), Escherichia
coli (B)a n dPseudomonas aeruginosa (C).
microorganisms and additional composites in the mixture.
For example, if a small volume of broth were added to the
reactionmixture,thelifeofcellsmightbeprolonged.Serum
proteins like albumin also extend the life span of microbes.
Figure 2 represents data on the antibacterial effects of var-
ious components of the C/MB/P solution challenged alone
and together, against three selected bacteria strains. In the
case of S. aureus (Figure 2A), a small trend of inhibition
of cell growth in the presence of each compound indi-
vidually is visible over the period of 24 h. However, the
C/MB/P acts much faster, lowering the concentration of
bacteria by a few logs in 30 min. Furthermore, after 24 h
viablebacteriawerenotdetected(P<0.01,C/MB/Pversus
sodium citrate alone). The combination of citrate and MB
progressively reduced the E. coli count (Figure 2B) to an
undetectable level after 24 h, but the C/MB/P acts more
quickly. The exposure of E. coli for only 30 min to C/MB/P
resulted in total elimination of living cells, as judged by the
abilitytoformcoloniesonanagarplate(P=0.07,C/MB/P
versus sodium citrate alone). The P. aeruginosa strain
(Figure 2C) was completely killed after 1–2-h exposure
to C/MB/P (P < 0.05 for C/MB/P versus sodium citrateAntimicrobial catheter lock solution 1941
Fig. 3. MIC of C/MB/P versus several pathogens (ATCC and hospital
isolates) expressed as % of the original concentration.
Fig. 4. Resistance study. Selected bacteria were grown in three different
concentrations of C/MB/P (MIC, below and above MIC) for 40 days.
Points on graph represent the highest concentration of the C/MB/P in
which cells constantly survived.
alone). The P. aeruginosa strain seems to be resistant to
citrate at pH 6.2 or citrate/MB mixture. Overall, these re-
sultsstronglysuggestsynergisticratherthanadditiveeffects
among components in tested product.
As can be seen from Figure 3, all tested organisms have
an MIC of 25% or less of the original concentration. Tested
bacteria did not develop resistance above this earlier de-
termined MIC over a long period of time. Figure 4 repre-
sents the first 40 days of the resistance development studies
with examples of gram-positive and gram-negative strains.
Both experiments indicate the high level of effectiveness of
this new lock solution in eliminating microorganisms and
thereby preventing catheter colonization with planktonic
microorganisms.
The C/MB/P also demonstrated antibacterial activity
againstsessilemicroorganismsinabiofilm.One-hourtreat-
mentofbiofilmgrowthoncarbothaneorglasscouponswith
the new CLS diminished viable cells practically to zero,
as shown in Figure 5. This was also true with antibiotic-
resistant strains from hospital isolates. To evaluate whether
human plasma proteins may enhance the biofilm resistance
Fig. 5. Formation and elimination of a biofilm on carbothane coupons
for different strains of bacteria and fungus. Duplicate coupons with a
biofilm were treated for 1 h with C/MB/P. Similar results were obtained
if carbothane coupons were presoaked in human plasma overnight before
the experiment.
toanewCLS,sterilecouponswereimmersedin10mlofhu-
man plasma and incubated overnight (37◦C and 160 RPM).
After that they were rinsed with saline, dried and treated
as described in the Methods section. The pretreatment of
the coupons in human plasma did not reduce potency of the
C/MB/P solution (data not shown).
The microscopic studies demonstrated that C/MB/P not
only kills bacteria within a biofilm but also removes the
biofilm and bacteria from the surface of coupons to a high
degree, as shown in Figure 6. As can be seen, the P. aerug-
inosa biofilm was almost totally removed after treatment
with the new CLS and only a few bacteria cells were found
to have survived (Figure 6A and B). Those that remained
on the coupon surface were seen in highly degraded form
usingAFM(Figure6CandD)andwereprobablydead.The
high killing efficiency of C/MB/P was confirmed by FM
with LIVE/DEAD
R   BacLightTM bacterial viability dye.
As can been seen in Figure 6E, the S. aureus biofilm be-
fore treatment stained mainly green because of unchanged
membrane structure of the cells. However, after exposure
to C/MB/P (Figure 6F), the biomass on the coupon was
reduced drastically and remaining cells were stained red
indicating cellular death.
Theresultsfromthecontinuousflowcellbioreactorshow
that the new CLS reduces biofilm formation by more than
four logs over 16 days in spite of repeated contamination,
compared to control and heparin samples. The results of
thisstudyalsodemonstratereductionofestablishedbiofilm
(48 h) on the surface of carbothane coupons (Figure 7).
Discussion
Heparin is used as a CLS to prevent or reduce thrombosis
of the catheter. It has been proposed that heparin, hav-
ing antibacterial properties, may avoid bacterial infection
with some strains [30,31]. Most available heparin solutions
contain preservatives such as benzyl alcohol (15 mg/ml)
or a mixture of MP (0.15%) and PP (0.015%). In our1942 J. Steczko et al.
Fig.6. Microscopicstudies.Scanningelectronmicroscopy(SEM)oftheP.aeruginosabiofilmoncarbothanecouponsbefore(A)andafter(B)treatment
with C/MB/P. Atomic force microscopy (AFM) of the P. aeruginosa biofilm developed on glass discs before (C) and after (D) treatment with
C/MB/P. Fluorescence microscopy (FM) of the S. aureus biofilm staining with LIVE/DEAD
R   BacLightTM bacterial viability dye. Dense biofilm with
mainly live cells staining green (E) was drastically reduced after 1 exposure to C/MB/P. Remaining cells are stained red (F) indicating the antibiofilm
efficacy of C/MB/P.
comparison studies,wechallenged microorganisms against
the heparin solution containing 2500 units/ml and 0.75
mg/ml MP and 0.075 mg/ml PP. The possible binding of di-
valent cations by heparin [30], and the presence of antisep-
tics may have some impact on microbial inhibition of hep-
arin solutions. However, in recent publications heparin is
noted to promote biofilm formation, especially for Staphy-
lococcus[32].Somehaveproposedthatheparincontributes
to the risk of CRBSI whenever it is used as a lock solution
between dialysis treatments [33]. Our studies did not show
any antibacterial effectiveness of heparin with parabens
(Figure 1), which agrees with many recently published dataAntimicrobial catheter lock solution 1943
Fig. 7. Comparison of C/MB/P and heparin effectiveness against the
S. aureus biofilm developed in a flow cell reactor. C/MB/P ‘clean’ refers
totheexperimentwhenoriginallycleancouponsweredailychallengedfor
3 h with S. aureus. C/MB/P ‘dirty’ refers to the experiment when coupons
first were challenged in a bioreactor with S. aureus f o r4 8ha n dt h e n
exposed continuously to test CLS.
[34–36]. A weak antimicrobial efficacy of heparin with
parabens was observed only for a few organisms and after
a long time of incubation (48–72 h).
Because of the development of bacterial resistance, an-
tibiotic CLSs are considered to be inappropriate for some
bacterial strains (e.g. S. aureus) that have an elevated rate
of therapeutic failure [37,38]. Sensitization of the patients
to aminoglycosides may also take place, and continuous
exposure to these antibiotics in CLS is not advisable.
There is a renewed interest in citrate as an alternative
to heparin in a CLS, because of its antithrombotic and
antibacterial properties, reduced costs relative to heparin
and lack of heparin complications. Citrate as CLS has been
used in a wide range of concentrations from 4 to 46.7%
[5,39–41]. In 2000, we demonstrated antimicrobial activity
of sodium citrate, especially in higher concentrations (10–
47%) [40]. Clinical trials have confirmed a decrease in
CRBSIusing30%sodiumcitratecontrastedtoheparin[35],
but there are potential risks when used in such range of
strength [42]. Report of a fatal cardiac arrest following
the direct injection of 10 ml of a high concentration of
trisodium citrate (46.7%) led to the restriction of use of a
commercially marketed product, Tricitrosol, by the FDA
[43]. Therefore, it is unlikely that higher concentrations of
citrate,suchas30–47%,willbeallowedbyFDAbecauseof
persistent fears of myocardial toxicity from hypocalaemia
if an administration error is made.
Studies of dilute sodium citrate formulation as CLS (4%
orless)havedemonstratedefficacyasananticoagulantwith




been several comparisons of the efficacy, safety and cost of
citrate versus heparin as CLS [50,51]. Conversely, differ-
enceswerenotdetectedwithrespecttonumberofinfections
when comparing citrate 4% with heparin. An in vitro study
demonstrated that sodium citrate at a concentration >0.5%
might inhibit biofilm formation and cell growth of S. au-
reus and S. epidermidis and by so doing reduce the risk of
biofilm-associated complications in indwelling catheters
[52]. On the other hand, it was determined that even 4%
citrate did not disrupt pre-existing biofilms.
C/MB/P is a unique combination of several compounds
with a carefully balanced concentration to assure safety.
Seven percent citrate (trisodium citrate/citric acid pH 6.2)
has excellent anticoagulation properties, capability to pre-
vent growth of many microorganisms as compared to a
saline control (Figure 2), and has a density of 1.040 very
closetothebloodofpatientswithESRDandmildanaemia.
Thisdensitydiminishesthehydraulicforcesthatcanreplace
the CLS with blood. MB, one of a large group of phenoth-
iazinedyes,hasinherentmicrobialtoxicitythroughreactive
singlet oxygen [53–55] and redox potential of the dye [56].
It is a cationic dye and may interact with the membrane or
cell wall of bacteria [57]. MB is often given intravenously
at a dosage of 1–7 mg/kg of body weight. The new CLS
contains only 2.5 mg of MB in the total volume of catheter
lock.Inourexperiments,thecombinationof7%citratewith
0.05% MB resulted in partial (S. aureus) to total (E. coli)
elimination of bacteria strains, but this required up to 24-h
period of incubation. However, as is also shown in Figure
2(C), the P. aeruginosa strain seems to be not affected by
citrateorcitrate/MBmixture.SimilarbehaviourofP.aerug-
inosa in a lower concentration of citrate was observed ear-
lier [35] and may have been due to utilization of the citrate
ionasanutrientbythesebacteriaintherangeofneutralpH.
Parabensarewell-knownantibacterialagents,andthisisthe
reason that they are used as preservatives in medicine, cos-
metic and food industries. The biocidal activity increases
with the length of the hydrocarbon alkyl chain, but solu-
bility drastically decreases. Thus, the parabens are often
used in combination, mainly methyl and propyl parabens
[58,59]. They are used widely for intravenous fluids con-
tained in multiple use vials, as well as topical applications
in concentrations generally <1% (w/w) [58,59]. They are
considered to be safe [60] although at a high concentra-
tion in skin treatments there is uncertainty about estro-
genic potential. Parabens concentrations in tested formu-
lation are much lower than the concentration used in skin
preparations. Alone in the citrate solution, they preserve
growth of microbes slightly better than citrate by itself, but
elimination of living cells is limited. On the other hand,
when all components are mixed together in the final prod-
uct, microbial inactivation properties are surprisingly high.
They reveal a synergistic effect as a mixture by eradicat-
ing in a short time all tested strains of bacteria and fungi.
Microbial reductions above 99% were obtained in the first
few minutes of incubation. One to two hours contact of the
newCLSwithtestedplanktonicbacteriastrainsirreversibly
eliminates all living bacteria. The time interval for killing
fungi was somewhat longer but still did not exceed 24 h.
All organisms have an MIC of 25% or less of the original
concentration of C/MB/P, and antimicrobial properties are
not diminished in the presence of media and 5% albumin.
Thisleadstotheconclusionthatthislocksolutionshouldbe
effective in killing bacteria even in the presence of blood at
the tip of the catheter. There was no change in the MIC over
a long period of time as shown by the microbial resistance
experiment. Other studies (not shown) have demonstrated
safety and lack of toxicity of the new lock solution.1944 J. Steczko et al.
The C/MB/P solution also appears to prevent formation
of a biofilm or to eradicate sessile bacteria from the surface
of polymers used in catheter manufacturing. When poly-
meric or glass coupons were exposed to media inoculated
with bacteria, biofilm formation was confirmed within
hours for all tested microorganisms. After biofilms were
grown for a 24-h period, coupons with a biofilm were im-
mersed in C/MB/P. One-hour treatment of biofilm growth
on carbothane or glass coupons with C/MB/P diminished
viable cells to nearly undetectable levels. This happened
also with antibiotic-resistant strains from hospital isolates.
Pretreatingthecouponswithhumanplasmabeforecreation
of the biofilms did not reduce the potency of C/MB/P. Mi-
croscopic methods disclosed that the C/MB/P not only kills
microorganisms on carbothane or glass discs but also phys-
ically removes a biofilm from the surface to a high degree.
After treatment, few bacterial cells were found to have sur-
vived. Those that remained on the coupon surface were
mainly dead as confirmed by FM and appeared highly de-
graded on AFM. These results were supported by flow cell
bioreactor experiments with a clinical isolate of S. aureus.
C/MB/P significantly reduced biofilm formation by four
logs even if challenged daily by bacteria for 3 h. It also has
asignificantimpactineradicationoflivingorganismsfrom




tonic and sessile microorganisms. The study also confirms
physical elimination of a biofilm and lack of development
of resistance. Elimination of bacteria from a catheter lu-
men, prevention of biofilm formation and eradication of
bacteria in the existing biofilm are all important if a CLS
is to diminish the incidence of CRBSI. A clinical trial
(AZEPTIC) with 415 enrolled patients has just been com-
pleted, to compare effects of C/MB/P versus heparin on
CRBSI incidence and patency of CVC for dialysis.
Acknowledgements. The authors thank Bacterin International, Inc.
(Belgrade MT, USA), for help in the design and performance of flow
cell bioreactor studies.
Conflict of interest statement. There has been no research support re-
ceived from granting agencies or industry sources used to generate the
information disclosed in this publication. J.S., L.B., and R.W. are full-
time employees of Ash Access Technology, Inc. S.R.A. (Chairman & Dir.
R&D) is a part-time paid consultant with the Company. All own shares




1. Tokars JI. Description of a new surveillance system for bloodstream
and vascular access infections in outpatient hemodialysis centers.
Semin Dial 2000; 13: 97–100
2. Allon M, Depner TA, Radeva M et al. Impact of dialysis dose and
membrane on infection-related hospitalization and death: results of
the HEMO Study. J Am Soc Nephrol 2003; 14: 1863–1870
3. Finelli L, Miller JT, Tokars JI et al. National surveillance of dialysis-
associated diseases in the United States, 2002. Semin Dial 2005; 18:
52–61
4. Klevens RM, Tokars JI, Andrus M. Electronic reporting of infections
associated with hemodialysis. Nephrol News Issues 2005; 19: 37–38,
43
5. Weijmer MC, Van Den Dorpel MA, Van de Ven PJ et al. Random-
ized, clinical trial comparison of trisodium citrate 30% and heparin as
catheter-locking solution in hemodialysis patients. J Am Soc Nephrol
2005; 16: 2769–2777
6. McIntyreCW,HulmeLJ,TaalMetal.Lockingoftunneledhemodial-
ysis catheters with gentamicin and heparin. Kidney Int 2004; 66: 801–
805
7. Dogra GK, Herson H, Hutchison B et al. Prevention of tunneled
hemodialysis catheter-related infections using catheter-restricted fill-
ing with gentamicin and citrate: a randomized controlled study. JA m
Soc Nephrol 2002; 13: 2133–2139
8. Johnson DW, MacGinley R, Kay TD et al. A randomized controlled
trial of topical exit site mupirocin application in patients with tun-
nelled,cuffedhaemodialysiscatheters.NephrolDialTransplant2002;
17: 1802–1807
9. Lok CE, Stanley KE, Hux JE et al. Hemodialysis infection prevention
with polysporin ointment. J Am Soc Nephrol 2003; 14: 169–179
10. FeelyT,CopleyA,BleyerAJ.Catheterlocksolutionstopreventblood-
stream infections in high-risk hemodialysis patients. Am J Nephrol
2007; 27: 24–29
11. Kim SH, Song KI, Chang JW et al. Prevention of uncuffed hemodial-
ysis catheter-related bacteremia using an antibiotic lock technique: a
prospective, randomized clinical trial. Kidney Int 2006; 69: 161–164
12. Saxena AK, Panhotra BR, Sundaram DS et al. Enhancing the survival
of tunneled haemodialysis catheters using an antibiotic lock in the el-
derly: a randomised, double-blind clinical trial. Nephrology (Carlton)
2006; 11: 299–305
13. Nori US, Manoharan A, Thornby JI et al. Mortality risk factors in
chronic haemodialysis patients with infective endocarditis. Nephrol
Dial Transplant 2006; 21: 2184–2190
14. Bleyer AJ, Mason L, Russell G et al. A randomized, controlled trial
of a new vascular catheter flush solution (minocycline-EDTA) in tem-
porary hemodialysis access. Infect Control Hosp Epidemiol 2005; 26:
520–524
15. BetjesMG,vanAgterenM.Preventionofdialysiscatheter-relatedsep-
sis with a citrate-taurolidine-containing lock solution. Nephrol Dial
Transplant 2004; 19: 1546–1551
16. Labriola L, Crott R, Jadoul M. Preventing haemodialysis catheter-
related bacteraemia with an antimicrobial lock solution: a meta-
analysis of prospective randomized trials. Nephrol Dial Transplant
2008; 23: 1666–1672
17. Jaffer Y, Selby NM, Taal MW et al. A meta-analysis of hemodial-
ysis catheter locking solutions in the prevention of catheter-related
infection. Am J Kidney Dis 2008; 51: 233–241
18. Allon M. Prophylaxis against dialysis catheter-related bacteremia: a
glimmer of hope. Am J Kidney Dis 2008; 51: 165–168
19. O’Grady NP, Alexander M, Dellinger EP et al. Guidelines for the
prevention of intravascular catheter-related infections. Am J Infect
Control 2002; 30: 476–489
20. Mermel LA. Prevention of intravascular catheter-related infections.
Ann Intern Med 2000; 132: 391–402
21. Polaschegg HD, Shah C. Overspill of catheter locking solution: safety
and efficacy aspects. ASAIO J 2003; 49: 713–715
22. Guerraoui A, Dacosta EE, Roche BB et al. Emergence of multiresis-
tantStaphylococcusepidermidis(MRSE)afterlockantibioticregimen
bygentamicininpermanenthemodialysiscatheters.Perspectivestudy,
1999–2003 (Abstract). J Am Soc Nephrol 2004 ; 15: 368A
23. Karaaslan H, Peyronnet P, Benevent D et al. Risk of heparin lock-
related bleeding when using indwelling venouscatheter in haemodial-
ysis. Nephrol Dial Transplant 2001; 16: 2072–2074
24. Bauer E, Derfler K, Joukhadar C et al. Citrate kinetics in patients
receiving long-term hemodialysis therapy. Am J Kidney Dis 2005; 46:
903–907
25. Fux CA, Stoodley P, Hall-Stoodley L et al. Bacterial biofilms: a
diagnostic and therapeutic challenge. Expert Rev Anti Infect Ther
2003; 1: 667–683Antimicrobial catheter lock solution 1945
26. Manierski C, Besarab A. Antimicrobial locks: putting the lock on
catheter infections. Adv Chronic Kidney Dis 2006; 13: 245–258
27. LokCE.Avoidingtroubledowntheline:themanagementandpreven-
tion of hemodialysis catheter-related infections. Adv Chronic Kidney
Dis 2006; 13: 225–244
28. Bleyer AJ. Use of antimicrobial catheter lock solutions to prevent
catheter-related bacteremia. Clin J Am Soc Nephrol 2007; 2: 1073–
1078
29. Standards NCfCL. M23-A2, vol. 21, no. 7. National Committee for
Clinical Laboratory Standards, Wayne, PA, 2000
30. Rosett W, Hodges GR. Antimicrobial activity of heparin. J Clin
Microbiol 1980; 11: 30–34
31. Zappala C, Chandan S, George N et al. The antimicrobial effect of
heparin on common respiratory pathogens. Crit Care Resusc 2007; 9:
157–160
32. Shanks RM, Donegan NP, Graber ML et al. Heparin stimulates
Staphylococcus aureus biofilm formation. Infect Immun 2005; 73:
4596–4606
33. Mandolfo S, Borlandelli S, Elli A. Catheter lock solutions: it’s time
for a change. J Vasc Access 2006; 7: 99–102
34. LaPlante KL, Mermel LA. In vitro activity of daptomycin and van-
comycinlocksolutionsonstaphylococcalbiofilmsinacentralvenous
catheter model. Nephrol Dial Transplant 2007; 22: 2239–2246
35. Weijmer MC, Debets-Ossenkopp YJ, Van De Vondervoort FJ et al.
Superior antimicrobial activity of trisodium citrate over heparin for
catheter locking. Nephrol Dial Transplant 2002; 17: 2189–2195
36. Nori US, Manoharan A, Yee J et al. Comparison of low-dose gentam-
icin with minocycline as catheter lock solutions in the prevention of
catheter-related bacteremia. Am J Kidney Dis 2006; 48: 596–605
37. Fernandez-Hidalgo N, Almirante B, Calleja R et al. Antibiotic-lock
therapy for long-term intravascular catheter-related bacteraemia: re-
sults of an open, non-comparative study. J Antimicrob Chemother
2006; 57: 1172–1180
38. Maya ID, Carlton D, Estrada E et al. Treatment of dialysis catheter-
related Staphylococcus aureus bacteremia with an antibiotic lock: a
quality improvement report. Am J Kidney Dis 2007; 50: 289–295
39. Stas KJ, Vanwalleghem J, De Moor B et al. Trisodium citrate 30%
vs. heparin 5% as catheter lock in the interdialytic period in twin-
or double-lumen dialysis catheters for intermittent haemodialysis.
Nephrol Dial Transplant 2001; 16: 1521–1522
40. Ash SR, Mankus RA, Sutton JM et al. Concentrated sodium citrate
(23%) for catheter lock. Hemodial Int 2000; 4: 22–31
41. Bayes B, Bonal J, Romero R. Sodium citrate for filling haemodialysis
catheters. Nephrol Dial Transplant 1999; 14: 2532–2533
42. Polaschegg HD, Sodemann K. Risks related to catheter locking solu-
tions containing concentrated citrate. Nephrol Dial Transplant 2003;
18: 2688–2690
43. FDA. FDA issues warning on TriCitrasol dialysis catheter anticoag-
ulant. April 2000
44. Branson PK, McCoy RA, Phillips BA et al. Efficacy of 1.4 percent
sodium citrate in maintaining arterial catheter patency in patients in a
medical ICU. Chest 1993; 103: 882–885
45. ButurovicJ,PonikvarR,KandusAetal.Fillinghemodialysiscatheters
in the interdialytic period: heparin versus citrate versus polygeline. a
prospective randomized study. Artif Organs 1998; 22: 945–947
46. Michaud D, Komant T, Pfefferle P. Four percent trisodium citrate as
an alternative anticoagulant for maintaining patency of central venous
hemodialysis catheters: case report and discussion. A mJC r i tC a r e
2001; 10: 351–354
47. Hendrickx L, Kuypers D, Evenepoel P et al. A comparative prospec-
tive study on the use of low concentrate citrate lock versus heparin
lock in permanent dialysis catheters. Int J Artif Organs 2001; 24:
208–211
48. Meeus G, Kuypers DR, Claes K et al. A prospective, randomized,
double-blind crossover study on the use of 5% citrate lock versus 10%
citrate lock in permanent hemodialysis catheters. Blood Purif 2005;
23: 101–115
49. Grudzinski L, Quinan P, Kwok S et al. Sodium citrate 4% locking
solutionforcentralvenousdialysiscatheters—aneffective,morecost-
efficient alternative to heparin. Nephrol Dial Transplant 2007; 22:
471–476
50. Lok CE, Appleton D, Bhola C et al. Trisodium citrate 4%—an alter-
native to heparin capping of haemodialysis catheters. Nephrol Dial
Transplant 2007; 22: 477–483
51. MacRaeJM,DojcinovicI,DjurdjevOetal.Citrate4%versusHeparin
and the Reduction of Thrombosis Study (CHARTS). Clin J Am Soc
Nephrol 2008; 3: 369–374
52. ShanksRM,SargentJL,MartinezRMetal.Catheterlocksolutionsin-
fluencestaphylococcalbiofilmformationonabioticsurfaces.Nephrol
Dial Transplant 2006; 21: 2247–2255
53. Wainwright M, Crossley KB. Methylene blue—a therapeutic dye for
all seasons? J Chemother 2002; 14: 431–443
54. Wainwright M, Phoenix DA, Laycock SL et al. Photobactericidal
activity of phenothiazinium dyes against methicillin-resistant strains
of Staphylococcus aureus. FEMS Microbiol Lett 1998; 160: 177–181
55. Usacheva MN, Teichert MC, Biel MA. Comparison of the methy-
lene blue and toluidine blue photobactericidal efficacy against gram-
positive and gram-negative microorganisms. Lasers Surg Med 2001;
29: 165–173
56. Rice L, Phoenix DA, Wainwright M et al. Effect of increasing methy-
lation on the ability of methylene blue to cause diaphorase-catalysed
oxidation of NADH. Biochem Soc Trans 1998; 26: S319
57. UsachevaMN,TeichertMC,BielMA.Theinteractionoflipopolysac-
charides with phenothiazine dyes. Lasers Surg Med 2003; 33: 311–
319
58. Soni MG, Burdock GA, Taylor SL et al. Safety assessment of propyl
paraben:areviewofthepublishedliterature.FoodChemToxicol2001;
39: 513–532
59. Soni MG, Taylor SL, Greenberg NA et al. Evaluation of the health
aspects of methyl paraben: a review of the published literature. Food
Chem Toxicol 2002; 40: 1335–1373
60. Soni MG, Carabin IG, Burdock GA. Safety assessment of esters of
p-hydroxybenzoicacid(parabens).FoodChemToxicol2005;43:985–
1015
Received for publication: 31.7.08; Accepted in revised form: 27.12.08